Ultragenyx Pharmaceutical Inc. has successfully completed the sale of its Rare Pediatric Disease Priority Review Voucher (PRV) for $210 million. This transaction, finalized on October 30, 2026, is a significant step for the company, enhancing its financial position and strategic outlook.

The PRV was awarded to Ultragenyx by the U.S. Food and Drug Administration (FDA) on August 19, 2026, following the approval of its treatment, GENGLYCOS® (pariglasgene brecaparvovec-opnr), for glycogen storage disease type Ia (GSDIa). This sale is part of a broader trend in the pharmaceutical industry, where companies are increasingly leveraging PRVs to boost their financial resources.

Background

Ultragenyx Pharmaceutical Inc. is a biopharmaceutical company focused on developing innovative products for rare diseases. The company operates under the Standard Industrial Classification (SIC) code 2834, which pertains to Pharmaceutical Preparations. It trades under the ticker symbol RARE on the Nasdaq exchange. The company is incorporated in Delaware and has a fiscal year ending on December 31.

What the Filing Says

According to the recent SEC filing (accession number 0001193125-26-445342), "On October 30, 2026, Ultragenyx Pharmaceutical Inc. completed the previously disclosed sale of its Rare Pediatric Disease Priority Review Voucher to the buyer." The filing further states that the company received gross proceeds of $210 million from this transaction.

Impact

This transaction not only strengthens Ultragenyx's financial standing but also highlights the growing significance of pediatric treatments in the pharmaceutical industry. The company is required to pay 20% of the gross proceeds from the PRV sale to the National Institutes of Health (NIH), as stipulated in a patent license agreement dated December 10, 2018. This financial commitment reflects the collaborative nature of pharmaceutical development and the importance of funding research in rare diseases.

What's Next

The filing does not specify what happens next for Ultragenyx following this sale. However, the company plans to include the full text of the PRV Asset Purchase Agreement in its upcoming Annual Report on Form 10-K for the year ended December 31, 2026, which will provide further insights into the implications of this transaction.